高危基因突变携带者前列腺癌的临床管理
Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.
作者信息
Clark Roderick, Herrera-Caceres Jaime, Kenk Miran, Fleshner Neil
机构信息
Division of Urology, University of Toronto, Toronto, ON M5G 1X6, Canada.
Department of Urology, Penn State Health, Hershey, PA 17033, USA.
出版信息
Cancers (Basel). 2022 Feb 16;14(4):1004. doi: 10.3390/cancers14041004.
BACKGROUND
Prostate cancer is a leading cause of death. Approximately one in eight men who are diagnosed with prostate cancer will die of it. Since there is a large difference in mortality between low- and high-risk prostate cancers, it is critical to identify individuals who are at high-risk for disease progression and death. Germline genetic differences are increasingly recognized as contributing to risk of lethal prostate cancer. The objective of this paper is to review prostate cancer management options for men with high-risk germline mutations.
METHODS
We performed a review of the literature to identify articles regarding management of prostate cancer in individuals with high-risk germline genetic mutations.
RESULTS
We identified numerous publications regarding the management of prostate cancer among high-risk germline carriers, but the overall quality of the evidence is low.
CONCLUSIONS
We performed a review of the literature and compiled clinical considerations for the management of individuals with high-risk germline mutations when they develop prostate cancer. The quality of the evidence is low, and there is an immediate need for further research and the development of consensus guidelines to guide clinical practice for these individuals.
背景
前列腺癌是主要的死亡原因之一。每八名被诊断患有前列腺癌的男性中约有一人会因此死亡。由于低风险和高风险前列腺癌的死亡率存在很大差异，识别出疾病进展和死亡风险高的个体至关重要。种系基因差异越来越被认为是导致致命性前列腺癌风险的因素。本文的目的是综述具有高风险种系突变男性的前列腺癌管理方案。
方法
我们对文献进行了综述，以确定有关具有高风险种系基因突变个体前列腺癌管理的文章。
结果
我们识别出了许多关于高风险种系携带者前列腺癌管理的出版物，但证据的总体质量较低。
结论
我们对文献进行了综述，并汇编了具有高风险种系突变个体患前列腺癌时管理的临床考量。证据质量较低，迫切需要进一步研究并制定共识指南以指导这些个体的临床实践。
Zotero 插件